PPA Category III status for safety in nasal decongestants tentatively decided -- FDA.
This article was originally published in The Tan Sheet
Executive Summary
PPA TO BE DESIGNATED CATEGORY III FOR SAFETY IN OTC NASAL DECONGESTANT and weight control products in upcoming proposed rules while additional safety data on the ingredient are being collected, FDA said in a May 17 letter to Caprice-Greystoke. The agency explained that its position on phenylpropanolamine hydrochloride (PPA)'s status in the pending proposed rules is "tentative." The letter responds to the company's third citizen petition on PPA, dated Dec. 8, 1995.
You may also be interested in...
Supplement GMP Warning Letters Make Modest Debut In 2010
Finalization of a settlement between the Federal Trade Commission and Rexall Sundown regarding unsupported cellulite treatment claims for the firm's Cellasene dietary supplement hinges upon approval of two related class action settlements pending in California and Florida, according to FTC
In Brief
Combe sells most of its OTC brands
People In Brief
Perrigo promotes in pricing, planning